

Purpose of the Meeting

This meeting will bring basic research scientists working on models of autoimmune disease relevant to lupus together with clinicians treating lupus patients. There are numerous mouse models of lupus, but their relevance to the actual disease is still a subject for debate. Thus it is the purpose of this meeting to have participants discuss similarities, as well as differences, in mouse models with respect to the disease with the clinicians who actually treat patients. In addition, input is encouraged from clinical attendees regarding what markers in an animal model would be most important for monitoring the disease and assessing the effectiveness of treatment. It is hoped that one consequence of this meeting might be some consensus as to what is most important in any animal model and what animal models might be most useful in developing new markers and treatments for the disease. For more information, including the agenda and registration for this conference, please see <http://web.ncifcrf.gov/events/SystemicLupus/default.asp>.

Contacts:

Howard Young: Senior Investigator, NCI, NIH; 301-846-5700; younghow@mail.nih.gov.

Silvia Bolland: Senior Investigator, NIAID, NIH; 301-443-3158; sb455w@nih.gov.

Juan Rivera: Senior Investigator, NIAMS, NIH; 301-496-7592; riveraj@mail.nih.gov.

Lisa Begg: Director of Research, ORWH, OD, NIH; 301-496-7853; begg@od.nih.gov.

Dated: May 5, 2010.

Francis S. Collins,

Director, National Institutes of Health.

[FR Doc. 2010-11169 Filed 5-10-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Population Sciences Subcommittee.

Date: June 17-18, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Gaylord National Hotel & Convention Center, 201 Waterford Street, National Harbor, MD 20745.

Contact Person: Carla T. Walls, PhD, Scientific Review Officer, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5b01, Bethesda, MD 20892, (301) 435-6898, walls@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: April 30, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-11073 Filed 5-10-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Cancer Institute; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information

concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board Ad hoc Subcommittee on Experimental Therapeutics.

Open: June 21, 2010, 6:30 p.m. to 8 p.m.

Agenda: Discussion on Experimental Therapeutics.

Place: Embassy Suites, Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Dr. Joseph Tomaszewski, Executive Secretary, NCAB Ad hoc Subcommittee on Experimental Therapeutics, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD 20892-8345, (301) 496-8531.

Name of Committee: National Cancer Advisory Board.

Open: June 22, 2010, 8 a.m. to 4 p.m.

Agenda: Program reports and presentations; business of the Board.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Name of Committee: National Cancer Advisory Board.

Closed: June 22, 2010, 4 p.m. to adjournment.

Agenda: Review of grant applications.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Name of Committee: National Cancer Advisory Board.

Open: June 23, 2010, 8:30 a.m. to 12 p.m.

Agenda: Program reports and presentations; business of the Board.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on